Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 25, 2026

Essential Utilities Reports Financial Results for Full Year 2025

View original at finance.yahoo.com
Essential Utilities Reports Financial Results for Full Year 2025 Earnings per share increases to $2.20 for Full Year 2025 Record $1.4 billion invested in infrastructure during the year Shareholder approval secured for announced merger with American Water BRYN MAWR, Pa., February 25, 2026--(BUSINESS WIRE)--Essential Uti…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With shareholder approval of merger with American Water, company is well-positioned to deliver for stakeholders for generations to come

    80% confidence

  • Merger with American Water remains on track for closing in the first quarter of 2027

    80% confidence

  • Team achieved excellence in operations, continuing to execute $450 million PFAS capital plan and exceeding Intelis gas meter installation goal

    80% confidence

  • Pipeline of potential water and wastewater municipal acquisitions represents approximately 400,000 total customers

    80% confidence

  • Anticipated growth in long-term earnings per share at a compounded annual growth rate of 5 to 7% from adjusted 2024 earnings per share of $1.97 for three-year period through 2027

    80% confidence

  • 2025 was truly a banner year for the company

    80% confidence

  • In 2026, regulated infrastructure investments are expected to be $1.7 billion

    80% confidence

  • Company has multiyear plan to ensure that finished water does not exceed federal maximum contaminant level of six EPA-regulated PFAS chemicals

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com